Skip to main content
HCPCS J3268 · Level II · Part B drug

J3268: delafloxacin (Baxdela), HCPCS Level II J code

Compiled from CMS files by the QuickIntell RCM Editorial Team · Data effective · Method: reference methodology · Report a data correction

Data currency: ASP payment limits: October 2026 (effective October 1, 2026); NCCI MUE tables: 2026 Q4 (effective October 1, 2026); NCCI PTP edits: v323r0 (2026 Q4) (effective October 1, 2026); OPPS Addendum B: October 2026 (effective October 1, 2026); ASC Addendum BB (covered ancillary services): October 2026 (effective October 1, 2026). Next CMS release: January 1, 2027 (quarterly update).

Key facts for J3268

Billing unit
1 MG
Injection, delafloxacin
ASP payment limit
$0.478
October 2026
Practitioner MUE
none published
CMS publishes no MUE for this code
OPPS status
SI E2
NCCI exposure
no PTP pairs
Coverage articles
0
none list this code

TL;DR

HCPCS J3268 is the Level II code for Injection, delafloxacin, 1 mg, billed per 1 MG. The Medicare Part B ASP payment limit for October 2026 is $0.478 per billing unit. Under OPPS it carries status indicator E2. With a 1 mg billing unit, a single administration can be hundreds of units; the unit count on the claim must equal the milligrams given, and rounding rules for partial units follow the contractor's guidance. The ASP crosswalk maps 1 NDC to it, sold as Baxdela by Melinta Therapeutics, LLC. No current Billing and Coding Article lists J3268, so coverage follows the FDA label, compendia and any applicable NCD.

Medicare Part B payment limit (ASP)

CMS sets the Part B payment limit for J3268 at $0.478 per 1 MG for October 2026, derived from manufacturer average sales price plus 6%. Beneficiary coinsurance is 20%.

ASP payment limits for J3268
QuarterPayment limitPerCoinsurance
October 2026$0.4781 MG20%
July 2026n/a1 MG—
CMS note: Added October 2026

NDC to HCPCS billing-unit conversion

The October 2026 ASP crosswalk maps 1 NDC from 1 labeler to J3268. Report the NDC in the claim's drug segment and bill the number of J3268 units that equals the quantity administered divided by 1 MG; the last column gives units per full package.

NDCs that crosswalk to J3268
NDCDrug nameLabelerPackage sizeBilling units / package
70842-0102-03BaxdelaMelinta Therapeutics, LLC1 × 103000

Medically Unlikely Edits (MUE)

CMS does not publish an MUE for J3268 in the 2026 Q4 tables. Some MUE values are confidential and applied without publication, so unit limits can still deny; document the dose and the units calculation on every claim.

MUE for J3268 in every setting opens the lookup with this code filled in, next to any other code on the same claim.

NCCI edits and add-on relationships

No active practitioner PTP pair lists J3268 as a column-1 or column-2 code in v323r0. Drug supply codes are rarely bundled; the administration codes billed with them are where PTP edits usually apply.

The counts above are exposure, not answers for a specific claim. Check J3268 against another code to see whether a given pair bundles, which code is paid and whether a modifier can separate them.

J3268 is neither an add-on code nor a designated primary code in the 2026 Q4 NCCI add-on edit file.

Medicare coverage articles

No current Billing and Coding Article lists J3268 in its HCPCS table. Coverage then follows the drug's FDA label, compendia and any National Coverage Determination; check the Medicare Coverage Database before administering off-label.

Hospital outpatient (OPPS) status

In the October 2026 OPPS Addendum B, J3268 carries status indicator E2. Status E indicates the item is not payable by Medicare under OPPS.

Ambulatory surgical center (ASC) payment

In the October 2026 ASC Addendum BB (covered ancillary services), J3268 carries payment indicator K5, which CMS defines as "Items, codes, and services for which pricing information and claims data are not available. No payment made". No separate national ASC rate is published for it.

Common denials for J3268 and how to prevent them

NDC missing, invalid or not matched to the HCPCS code

units billed exceed the MUE for the date of service

diagnosis not covered by the applicable coverage article or LCD

For teams evaluating QuickIntell software

Evaluate a coding workflow for J3268

Use the unit, NDC and edit questions in this reference to scope a QuickCode evaluation for qualified coder review, documentation clarification and the billing handoff. Confirm supported code sets, data inputs and reviewer responsibilities; the reference tables do not establish that a particular automated check or payer integration is available.

Optional software evaluation, not payer support or help with an individual claim. For coverage or payment decisions, use the official sources on this page. Do not include patient information in a demo booking or inquiry.

Frequently asked questions — HCPCS J3268

What does HCPCS code J3268 describe?

J3268 is defined by CMS as "Injection, delafloxacin, 1 mg". Each billing unit represents 1 MG, so the units reported on the claim must equal the dose administered divided by that unit.

Is J3268 a CPT code?

No. J3268 is a HCPCS Level II code, the letter-plus-four-digit set CMS maintains for drugs such as delafloxacin (Baxdela); CPT codes are five-character codes maintained by the AMA. On a Part B claim J3268 reports the drug itself in 1 mg units, and the administration is billed on its own line.

What is the Medicare reimbursement for J3268 in October 2026?

The ASP-based payment limit is $0.478 per 1 MG, with 20% beneficiary coinsurance. Commercial payers use their own fee schedules.

Which NDCs map to J3268?

The October 2026 ASP crosswalk lists 1 NDC from 1 labeler: Baxdela (Melinta Therapeutics, LLC). For example NDC 70842-0102-03 (package size 1) equals 3,000 billing units of J3268.

Does J3268 have NCCI bundling edits?

No active practitioner PTP pairs list J3268 as a column-1 or column-2 code in the v323r0 release.

Sources

Every figure on this page is taken from the CMS publications below, as released by the Centers for Medicare & Medicaid Services. Projection built 2026-11-16. Verify against the primary file before billing or contracting decisions. The reference methodology explains how each figure is computed from these files.

Disclaimer

This page is an operational reference compiled from CMS publications: the Medicare Part B drug payment limit and NDC crosswalk files, NCCI MUE and add-on edit tables, aggregate PTP statistics, OPPS Addendum B, ASC Addendum BB and the Medicare Coverage Database. Payment limits and rates are Medicare national amounts; commercial and Medicaid payers differ. CPT codes are shown as numbers only; CPT descriptors are copyright AMA. Nothing here is legal, clinical or billing advice.

Found a figure that does not match the CMS file? Report a data correction with the CMS file and the value you expected; the request reaches the editorial team through the contact form.